Despite weight loss and glycemic control, experts caution that type 2 diabetes remission is not a cure and that pancreatic ...

Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...

SGLT2 inhibitor use was not associated with an increased risk for postoperative diabetic ketoacidosis among patients with type 2 diabetes.

Are you ignoring the early signs of kidney disease in diabetes? As diabetic kidney disease is on the rise, here’s what ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher ...

A widely used diabetes medication, SGLT2 inhibitors, has shown a surprising benefit for cancer patients—protecting their ...

Researchers have identified in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT2i) could diminish the risk ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 on evaluation and ...

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

A drug already used to treat people who have diabetes and/or chronic kidney disease could have added heart disease benefits, ...